PuSH - Publication Server of Helmholtz Zentrum München

Hohenstein, B.* ; Bornstein, S.R.* ; Aringer, M.*

Immunoadsorption for connective tissue disease.

Atherosclerosis 14, 185-189 (2013)
DOI Order publishers version
Open Access Green as soon as Postprint is submitted to ZB.
Distinct connective tissue diseases (CTD's) such as systemic lupus erythematosus (SLE), systemic sclerosis, mixed connective tissue disease as well as dermato- and polymyositis comprise a group of diseases, where autoantibodies are not merely indicators of autoimmune disease, but also play an relevant role in the underlying pathogenicity. This knowledge led to the development of antibody targeting therapies using rituximab or belimumab. Upon this, therapeutic plasma exchange, and more recently immunoadsorption (IAS) have been successfully applied to remove pathogenic autoantibodies under various conditions in some of these CTD's. While the technique of IAS is superior to plasma exchange in regard to specificity and efficacy, the clinical use of IAS in CTD's is currently restricted to a small proportion of clinical situations with either refractory disease or the necessity to avoid aggressive immunosuppressive regimens. Despite the presence of a large number of case series and few controlled trials using IAS, there is a need for further prospective randomized trials to clearly define the role of IAS in these CTD's.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
ISSN (print) / ISBN 0021-9150
e-ISSN 1879-1484
Journal Atherosclerosis
Quellenangaben Volume: 14, Issue: 1, Pages: 185-189 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Amsterdam
Reviewing status Peer reviewed
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)